- Home
- RGC vs GBIO Comparison
RGC vs GBIO Comparison
Compare RGC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- GBIO
- Stock Information
- Founded
- RGC 2014
- GBIO 2016
- Country
- RGC Hong Kong
- GBIO United States
- Employees
- RGC N/A
- GBIO N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- GBIO Health Care
- Exchange
- RGC Nasdaq
- GBIO Nasdaq
- Market Cap
- RGC 171.1M
- GBIO 166.2M
- IPO Year
- RGC 2021
- GBIO 2020
- Fundamental
- Price
- RGC $6.52
- GBIO $2.82
- Analyst Decision
- RGC
- GBIO Buy
- Analyst Count
- RGC 0
- GBIO 4
- Target Price
- RGC N/A
- GBIO $7.50
- AVG Volume (30 Days)
- RGC 25.8K
- GBIO 74.2K
- Earning Date
- RGC 10-25-2024
- GBIO 11-07-2024
- Dividend Yield
- RGC N/A
- GBIO N/A
- EPS Growth
- RGC N/A
- GBIO N/A
- EPS
- RGC N/A
- GBIO N/A
- Revenue
- RGC N/A
- GBIO $13,174,000.00
- Revenue This Year
- RGC N/A
- GBIO $99.36
- Revenue Next Year
- RGC N/A
- GBIO N/A
- P/E Ratio
- RGC N/A
- GBIO N/A
- Revenue Growth
- RGC N/A
- GBIO 1397.05
- 52 Week Low
- RGC $3.03
- GBIO $0.86
- 52 Week High
- RGC $32.44
- GBIO $4.65
- Technical
- Relative Strength Index (RSI)
- RGC 46.56
- GBIO 55.13
- Support Level
- RGC $5.05
- GBIO $2.41
- Resistance Level
- RGC $7.24
- GBIO $2.75
- Average True Range (ATR)
- RGC 0.78
- GBIO 0.19
- MACD
- RGC -0.03
- GBIO 0.04
- Stochastic Oscillator
- RGC 50.52
- GBIO 95.93
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.